Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Prediction: 2 Stocks Will Be Worth More Than Palantir Technologies in 2026

In This Article:

Key Points

  • Palantir is currently worth $269 billion, but certain Wall Street analysts think Intuitive Surgical and ServiceNow can top that figure in 2026.

  • ServiceNow is a leader in IT service management and IT operations software, and recently released AI products are driving revenue growth.

  • Intuitive Surgical is a technology leader in robotics-assisted surgical systems, and it recently won new approvals from the FDA.

Palantir Technologies is currently worth $269 billion. But these Wall Street analysts think Intuitive Surgical (NASDAQ: ISRG) and ServiceNow (NYSE: NOW) can top that figure in 2026:

  • Patrick Wood at Morgan Stanley has set Intuitive Surgical with a bull-case target price of $850 per share. That implies 64% upside from its current share price of $517. It also implies a market value of $304 billion.

  • Patrick Walravens at JMP Securities has set ServiceNow at a target price of $1,300 per share. That implies 36% upside from its current share price of $955. It also implies a market value of $270 billion.

Here's what investors should know about these stocks.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Dollar sign against bar chart background.
Image source: Getty Images.

1. Intuitive Surgical

Intuitive Surgical is the leader in robotics-assisted surgery. It is best known for its da Vinci systems, which let surgeons perform minimally invasive procedures with greater precision in five areas:

  1. General surgery

  2. Urologic surgery

  3. Gynecologic surgery

  4. Cardiothoracic surgery

  5. Head and neck surgery

The company also provides Ion systems for minimally invasive lung biopsies.

Importantly, Intuitive has a razor-and-blade business model. Surgical and diagnostic systems are the razors; they represent significant but infrequent expenses for healthcare facilities. And the adjacent instruments and accessories are the blades; they include consumable tools like scalpels and forceps that must be replaced with each procedure. The razor-and-blade model creates a steady revenue stream.

Intuitive Surgical reported strong first-quarter financial results that beat estimates on the top and bottom lines. Revenue rose 19% to $2.2 billion on strong growth in da Vinci procedures and system placements. Meanwhile, non-GAAP (generally accepted accounting principles) earnings rose 21% to $1.50 per diluted share.

Intuitive is well positioned to keep its momentum. Recently, the company won approvals from the Food and Drug Administration that let da Vinci systems perform more colorectal surgical procedures. In a note to clients, Morgan Stanley analyst Patrick Wood said the total addressable market is "larger than investors might appreciate." So, the new approval could lead to faster-than-expected growth in the coming quarters.